One of last year’s best performing stocks, Sirtex Medical Limited
(ASX:SRX), is confident it can maintain the growth performance of the last five years.
The biotechnology and medical device company has today posted a 25 per cent jump in quarterly dose sales for its SIR-Spheres microspheres targeted radioactive liver cancer treatment.
Sales grew in all regions over the last three months of 2012, led by 37 per cent growth in the Asia Pacific and 29 per cent growth in the US. Sirtex says dose sales are a key measure of its performance and it has now posted 34 straight quarters of growth.
CEO Gilman Wong believes a high benchmark has been set for this year but remains confident Sixtex will continue to deliver growth.
In the 2012 financial year Sirtex Medical boosted its net profit to $17.1 million.
